Study guide

9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS)

PEBC Pharmacist Qualifying Examination Part I MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation

1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice

2 Chapter 2: Ethics, Scope of Practice & Safety Culture

2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement

3 Chapter 3: Pharmaceutical Calculations & Posology

3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)

4 Chapter 4: Compounding, Dispensing & Product Integrity

4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control

5 Chapter 5: Clinical Pharmacology & Pharmacokinetics

5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities

6 Chapter 6: Evidence-Based Medicine & Literature Appraisal

6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics

7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD

7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)

8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation

8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)

9 Chapter 9: Endocrine & Metabolic Disorders

9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)

10 Chapter 10: Respiratory & Gastrointestinal Disorders

10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis

11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship

11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections

12 Chapter 12: Central Nervous System & Mental Health

12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome

13 Chapter 13: Special Populations, Pain Management & Substance Use

13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy

14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care

14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care

15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health

15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder

16 Chapter 16: Immunization & Health Promotion

16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health

17 Chapter 17: Patient Care Process, Communication & Stewardship

17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship

9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS)

Key Takeaways Explain This Topic AI

Insulin analogs are categorized pharmacokinetically into rapid-acting (aspart, lispro, glulisine: onset 10–15 min, peak 1–2h), short-acting regular (onset 30 min, peak 2–3h), intermediate-acting (NPH: cloudy, peak 4–10h), and long/ultra-long-acting basal analogs (glargine, detemir, degludec: peakless, duration 24 to >42h).

Basal-bolus physiological replacement in type 1 diabetes allocates approximately 50% of the total daily dose (TDD) as basal insulin and 50% as rapid-acting prandial insulin divided across meals, utilizing the 500 Rule for insulin-to-carbohydrate ratios (ICR) and the 100 Rule (mmol/L) for insulin sensitivity factors (ISF).

Mild-to-moderate hypoglycemia (BG < 4.0 mmol/L) is managed with the Rule of 15: administer 15 g of fast-acting simple carbohydrate (e.g., 4 glucose tablets, 175 mL juice), retest in 15 minutes, repeat if BG remains < 4.0 mmol/L, and follow with a complex carbohydrate/protein snack if the next meal is > 1 hour away.

Severe hypoglycemia in an unconscious or incapacitated community patient requires emergency glucagon: 1 mg IM/SC or 3 mg nasal powder (Baqsimi); in healthcare settings with IV access, administer 20 to 50 mL of D50W slow IV push.

Diabetic ketoacidosis (DKA: high anion gap, positive ketones, pH < 7.30) and Hyperosmolar Hyperglycemic State (HHS: BG > 33.3 mmol/L, effective osmolality > 320 mOsm/kg) require immediate IV normal saline resuscitation, a mandatory potassium safety gate (hold insulin if K+ < 3.3 mmol/L), IV regular insulin at 0.1 units/kg/hr, and adding 5% dextrose once BG drops to 14.0–16.5 mmol/L.

Last updated: October 2026

9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS)

Exogenous insulin replacement is the mandatory, life-preserving therapy for all patients with type 1 diabetes mellitus (T1D) and represents a vital therapeutic modality for patients with type 2 diabetes who experience progressive β-cell exhaustion, severe symptomatic hyperglycemia, or acute metabolic decompensation. Mastering insulin pharmacokinetics, dose adjustment calculations, acute hypoglycemia rescue protocols, and the emergency management of diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) is foundational for Canadian pharmacy practice.

Insulin Pharmacology & Pharmacokinetic Classification

Therapeutic insulins are classified based on their onset, peak effect, and duration of action. Modern recombinant human insulin analogs have largely superseded regular human insulin and NPH for daily maintenance regimens because their modified amino acid sequences prevent hexamer stabilization or promote controlled depot precipitation, better mimicking physiological pancreatic secretion. INSULIN TIME-ACTION PROFILES

  • [Plasma Insulin]
  • │
  • │ Rapid-acting (Aspart, Lispro, Glulisine)
  • │ Onset 10-15m, Peak 1-2h, Duration 3-5h
  • │ ┌───┐
  • │ ╱ ╲ Regular Human (Toronto)
  • │ ╱ ╲ Onset 30m, Peak 2-3h, Duration 5-8h
  • │ ╱ ╲ ┌───────┐
  • │╱ ╲ ╱ ╲ NPH (Cloudy)
  • │ ╲ ╱ ╲ Onset 1-3h, Peak 4-10h, Duration 12-18h
  • │ ╲╱ ╲ ┌─────────────┐
  • │ ╲ ╱ ╲
  • │ Long-acting Basal (Glargine, Degludec) ─────────────────────────── Duration 24 - 42+ hours (Flat/Peakless)
  • └───────────────────────────────────────────────────────────────────
  • 0 1 2 3 4 5 6 7 8 9 10 12 16 20 24 Hours
  • Comprehensive Pharmacokinetic Comparison

Insulin Category Generic Name (Brand Examples) Physical Appearance Onset Peak Effect Effective Duration Clinical Role & Administration Nuances

Ultra-Rapid-Acting Analogs Faster aspart ( Fiasp ), Lispro-aabc ( Lyumjev ) Clear solution 2–5 min 45–60 min 3–5 hours Formulated with excipients (niacinamide, treprostinil) to accelerate hexamer dissociation; inject at start of meal or up to 20 min post-meal.

Rapid-Acting Analogs Insulin aspart ( NovoRapid ), Insulin lispro ( Humalog ), Insulin glulisine ( Apidra ) Clear solution 10–15 min 1–2 hours 3–5 hours First-line prandial insulin; inject 0 to 15 min before meals. Lower nocturnal hypoglycemia risk compared to Regular insulin.

Short-Acting (Regular) Regular Human Insulin ( Humulin R , Novolin ge Toronto ) Clear solution 30 min 2–3 hours 5–8 hours Inject 30 to 45 min before meals. Prone to late postprandial hypoglycemia. Preferred formulation for intravenous infusion in DKA and HHS.

Intermediate-Acting NPH / Isophane ( Humulin N , Novolin ge NPH ) Cloudy suspension 1–3 hours 4–10 hours 12–18 hours Protamine complexed; requires gentle rolling/inversion (10-20 times) before injection. High nocturnal hypoglycemia risk when injected at dinner/bedtime.

Long-Acting Basal Analogs Insulin glargine U-100 ( Lantus , Basaglar biosimilar), Insulin detemir ( Levemir ) Clear solution 1–2 hours Flat (No pronounced peak) ≈ 24 hours (Detemir 14–20 h, often split BID) Glargine is formulated at acidic pH 4.0; precipitates into microprecipitates upon SC injection at physiological pH 7.4. Never mix glargine in same syringe with other insulins.

Ultra-Long Basal Analogs Insulin glargine U-300 ( Toujeo ), Insulin degludec U-100/U-200 ( Tresiba ) Clear solution 1–2 hours Completely flat / peakless > 24 to 36 h (Toujeo); > 42 h (Degludec) Degludec forms soluble multi-hexamers in SC depot that slowly release monomers. Unrivaled dosing flexibility (can shift administration timing within an 8- to 40-hour window).

Important

Storage and Stability Protocol : Unopened insulin vials, cartridges, and pre-filled pens must be refrigerated at 2°C to 8°C and protected from light and freezing (freezing denatures the peptide structure, rendering it therapeutically inert). In-use insulins should be stored at room temperature (15°C to 30°C) to minimize local injection pain and lipodystrophy. Most in-use formulations are stable at room temperature for 28 days , with notable exceptions: insulin detemir is stable for 42 days , and insulin degludec and glargine U-300 are stable for 56 days .

Insulin Regimen Architecture in Type 1 Diabetes

Because individuals with type 1 diabetes experience absolute autoimmune destruction of pancreatic β-cells, exogenous therapy must replicate physiological insulin secretion: a continuous, low-level basal component (suppressing hepatic gluconeogenesis overnight and between meals) and sharp, episodic prandial (bolus) components (disposing of mealtime carbohydrate absorption).

Basal-Bolus Architecture

Starting Total Daily Dose (TDD) : Typically 0.5 units/kg/day in metabolically stable patients without ketoacidosis (range: 0.2–0.4 units/kg/day during the transient "honeymoon phase"; 0.6–1.0+ units/kg/day during acute illness, stress, or adolescent puberty).

Dose Allocation :

Basal Component : ≈ 50% of the TDD administered as a long-acting basal analog once daily (or split BID).

Prandial Component : ≈ 50% of the TDD divided approximately equally across three meals as a rapid-acting analog injected immediately before eating. EXAMPLE: 70 kg Patient Newly Diagnosed with Type 1 Diabetes

1. Calculate TDD: 70 kg * 0.5 units/kg/day = 35 units/day

2. Basal Component (50%): 35 units * 0.50 = 17.5 units -> Round to 17 or 18 units of Glargine or Degludec at bedtime

  • 3. Prandial Pool (50%): 35 units * 0.50 = 17.5 units rapid-acting analog across 3 meals
  • 4. Meal Allocation: ~6 units of Aspart or Lispro immediately before Breakfast, Lunch, and Dinner
  • Continuous Subcutaneous Insulin Infusion (CSII / Insulin Pumps)

Insulin pump therapy delivers an uninterrupted subcutaneous micro-infusion of rapid-acting insulin analog only (no basal insulin is ever loaded into an insulin pump). The pump delivers programmed basal rates (varying by hour to match physiological diurnal needs and counter the early morning "dawn phenomenon") plus patient-activated boluses for meals and hyperglycemic corrections.

Clinical Insulin Calculations: The 500 Rule & The 100 Rule

Patients practicing advanced carbohydrate counting calculate mealtime boluses based on their precise carbohydrate intake and pre-meal blood glucose.

1. Insulin-to-Carbohydrate Ratio (ICR): The 500 Rule

The Insulin-to-Carbohydrate Ratio (ICR) quantifies the number of grams of carbohydrate covered by 1 unit of rapid-acting insulin analog:

ICR (grams of carbohydrate / unit of insulin) = 500 Total Daily Dose (TDD) \text{ICR (grams of carbohydrate / unit of insulin)} = \frac{500}{\text{Total Daily Dose (TDD)}} ICR (grams of carbohydrate / unit of insulin) = Total Daily Dose (TDD) 500 ​

Carbohydrate Bolus Dose (units) = Grams of Carbohydrate Ingested ICR \text{Carbohydrate Bolus Dose (units)} = \frac{\text{Grams of Carbohydrate Ingested}}{\text{ICR}} Carbohydrate Bolus Dose (units) = ICR Grams of Carbohydrate Ingested ​

2. Insulin Sensitivity Factor (ISF / Correction Factor): The 100 Rule

The Insulin Sensitivity Factor (ISF) represents the expected reduction in blood glucose (in mmol/L) produced by 1 unit of rapid-acting insulin analog. In Canada, where blood glucose is measured in mmol/L, the 100 Rule is utilized (derived from the US 1800 Rule divided by 18):

ISF (mmol/L drop per unit of insulin) = 100 Total Daily Dose (TDD) \text{ISF (mmol/L drop per unit of insulin)} = \frac{100}{\text{Total Daily Dose (TDD)}} ISF (mmol/L drop per unit of insulin) = Total Daily Dose (TDD) 100 ​

Correction Bolus Dose (units) = Actual Blood Glucose − Target Blood Glucose ISF \text{Correction Bolus Dose (units)} = \frac{\text{Actual Blood Glucose} - \text{Target Blood Glucose}}{\text{ISF}} Correction Bolus Dose (units) = ISF Actual Blood Glucose − Target Blood Glucose ​

Step-by-Step Integrated Bolus Calculation

Clinical Scenario : A 60 kg adult with T1D has an established TDD of 50 units. The patient is preparing to eat a meal containing 60 g of carbohydrate. The pre-meal fingerstick blood glucose is 11.0 mmol/L, and the target preprandial blood glucose is 6.0 mmol/L.

Calculate the ICR : ICR = 500 50 = 10 g/unit \text{ICR} = \frac{500}{50} = 10\text{ g/unit} ICR = 50 500 ​ = 10 g/unit

Calculate the Carbohydrate Bolus : Carb Bolus = 60 g 10 g/unit = 6.0 units \text{Carb Bolus} = \frac{60\text{ g}}{10\text{ g/unit}} = 6.0\text{ units} Carb Bolus = 10 g/unit 60 g ​ = 6.0 units

Calculate the ISF : ISF = 100 50 = 2.0 mmol/L per unit \text{ISF} = \frac{100}{50} = 2.0\text{ mmol/L per unit} ISF = 50 100 ​ = 2.0 mmol/L per unit

Calculate the Correction Bolus : Correction Bolus = 11.0 mmol/L − 6.0 mmol/L 2.0 mmol/L/unit = 5.0 2.0 = 2.5 units \text{Correction Bolus} = \frac{11.0\text{ mmol/L} - 6.0\text{ mmol/L}}{2.0\text{ mmol/L/unit}} = \frac{5.0}{2.0} = 2.5\text{ units} Correction Bolus = 2.0 mmol/L/unit 11.0 mmol/L − 6.0 mmol/L ​ = 2.0 5.0 ​ = 2.5 units

Calculate Total Pre-Meal Bolus : Total Meal Dose = 6.0 units (Carb) + 2.5 units (Correction) = 8.5 units of rapid-acting insulin \text{Total Meal Dose} = 6.0\text{ units (Carb)} + 2.5\text{ units (Correction)} = 8.5\text{ units of rapid-acting insulin} Total Meal Dose = 6.0 units (Carb) + 2.5 units (Correction) = 8.5 units of rapid-acting insulin

Hypoglycemia Pathophysiology, Staging & Clinical Protocols

Hypoglycemia is the most frequent acute complication of insulin and secretagogue therapy, representing the primary limiting barrier to achieving optimal glycemic control.

Definition and Severity Staging

In individuals treated with insulin or sulfonylureas, hypoglycemia is defined as a plasma glucose concentration < 4.0 mmol/L , regardless of whether symptoms are recognized. HYPOGLYCEMIA SEVERITY SPECTRUM

  • ┌───────────────────────────────┬───────────────────────────────┬───────────────────────────────┐
  • │ MILD │ MODERATE │ SEVERE │
  • ├───────────────────────────────┼───────────────────────────────┼───────────────────────────────┤
  • │ Autonomic symptoms present: │ Autonomic + Neuroglycopenic: │ Involves severe cognitive │
  • │ Trembling, sweating, anxiety, │ Headache, confusion, mood │ impairment, unconsciousness, │
  • │ palpitations, hunger, nausea. │ changes, dizziness, weakness. │ or seizures. Patient REQUIRES │
  • │ Patient is conscious and ABLE │ Patient is conscious and ABLE │ ASSISTANCE OF ANOTHER PERSON │
  • │ to self-treat. │ to self-treat. │ to recover. (BG usually < 2.8)│
  • └───────────────────────────────┴───────────────────────────────┴───────────────────────────────┘
  • Management of Conscious Hypoglycemia: The Rule of 15
  • For any conscious patient with confirmed or suspected blood glucose < 4.0 mmol/L: THE RULE OF 15 FLOWCHART
  • Blood Glucose Confirmed < 4.0 mmol/L (or symptomatic)
  • │
  • ▼
  • INGEST 15 GRAMS FAST-ACTING CARBOHYDRATE
  • 4 chewable glucose tablets (4 g each = 16 g)
  • 175 mL (3/4 cup) fruit juice or regular soft drink
  • 6 Life Savers candies (chewed)
  • 3 teaspoons (15 mL) sugar or honey dissolved in water
  • │
  • ▼
  • REST AND WAIT EXACTLY 15 MINUTES
  • │
  • ▼
  • RE-TEST BLOOD GLUCOSE
  • │
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • STILL < 4.0 mmol/L? BG ≥ 4.0 mmol/L (RECOVERED)
  • │ │
  • ▼ ▼

Repeat 15 g fast-acting carb Is next meal > 1 hour away?

  • Wait 15 min & recheck blood glucose │
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • YES NO
  • │ │
  • ▼ ▼
  • Provide a snack with complex Proceed to scheduled meal
  • carbs + protein (e.g., bread & at regular time
  • peanut butter, or cheese & crackers)

Caution

Avoid Fat-Rich Foods for Acute Hypoglycemia : Patients must be counseled never to treat acute hypoglycemia with chocolate bars, pastries, whole milk, or ice cream. High dietary fat content markedly delays gastric emptying, delaying glucose absorption and prolonging the hypoglycemic state.

Management of Severe Hypoglycemia (Unconscious or Incapacitated)

When a patient is unconscious, seizing, or aggressive and unable to swallow safely:

Community / Pre-Hospital Emergency Interventions :

Call 911 / EMS immediately.

Place the patient in the lateral recovery position to prevent airway obstruction or aspiration from vomiting.

Do NOT attempt to administer oral fluids, glucose gels, or food into the mouth (aspiration hazard).

Administer Glucagon without delay:

Subcutaneous / Intramuscular Glucagon Injection Kit : 1 mg reconstituted powder injected IM into deltoid or anterior thigh.

Nasal Glucagon Powder (Baqsimi) : 3 mg single-use intranasal device. Actuated into one nostril; passively absorbed across nasal mucosa. Effective even if the patient is unconscious or has severe nasal congestion.

Once the patient regains consciousness and can swallow safely, provide oral fast-acting glucose followed by complex carbohydrates. Anticipate post-awakening nausea and vomiting.

Healthcare Setting with Established IV Access :

Administer Dextrose 50% in Water (D50W) : 20 to 50 mL (10 to 25 g of elemental dextrose) administered via slow IV push over 2 to 3 minutes. Re-check blood glucose within 10 to 15 minutes; follow with continuous 5% or 10% dextrose infusion if prolonged hypoglycemia is anticipated (e.g., sulfonylurea overdose).

Diabetic Emergencies: DKA versus HHS Comparative Framework

Diabetic Ketoacidosis (DKA) and Hyperosmolar Hyperglycemic State (HHS) represent life-threatening acute metabolic crises resulting from insulin deficiency coupled with counter-regulatory hormone surge (glucagon, catecholamines, cortisol, growth hormone). DKA vs. HHS PATHOPHYSIOLOGICAL DIVERGENCE

  • ABSOLUTE INSULIN DEFICIENCY RELATIVE INSULIN DEFICIENCY
  • (Classic DKA) (Classic HHS)
  • │ │
  • Massive Lipolysis in Adipocytes Minimal Residual Insulin Present
  • │ (Suppresses Lipolysis & Ketogenesis)
  • ▼ │
  • Free Fatty Acids -> Liver Beta-Oxidation ▼
  • │ Uncontrolled Hepatic Gluconeogenesis
  • ▼ │
  • KETONE BODY GENERATION ▼
  • (Beta-Hydroxybutyrate & Acetoacetate) EXTREME HYPERGLYCEMIA (> 33.3 mmol/L)
  • │ │
  • ▼ ▼
  • HIGH ANION GAP METABOLIC ACIDOSIS MASSIVE OSMOTIC DIURESIS
  • (pH < 7.30, HCO3 < 15, Kussmaul Breathing) Severe Dehydration (8-12 L Deficit)
  • Hyperosmolality (> 320 mOsm/kg)
  • Altered Mental Status / Coma
  • Diagnostic Comparison: DKA vs. HHS

Diagnostic Parameter Diabetic Ketoacidosis (DKA) Hyperosmolar Hyperglycemic State (HHS)

Primary Population Typically Type 1 Diabetes (can occur in ketosis-prone T2D) Typically Type 2 Diabetes (often elderly with acute infection/infarction)

  • Onset Timeline Acute: Rapid over < 24 hours Insidious: Develops slowly over days to weeks
  • Plasma Glucose > 14.0 mmol/L (frequently 20–35 mmol/L) Markedly elevated: > 33.3 mmol/L (often > 50–60 mmol/L)

Arterial / Venous pH Acidotic : Mild 7.25–7.30; Moderate 7.00–7.24; Severe < 7.00 Normal or mildly reduced: > 7.30

Serum Bicarbonate Low : < 15–18 mmol/L (Severe < 10 mmol/L) Normal: > 18 mmol/L

Serum / Urine Ketones Strongly positive (Serum β-hydroxybutyrate ≥ 3.0 mmol/L) Absent, trace, or mildly positive

  • Serum Anion Gap Elevated (> 10–12 mmol/L): [Na+] - ([Cl-] + [HCO3-]) Usually normal (< 12 mmol/L)
  • Effective Serum Osmolality Variable, typically < 320 mOsm/kg Severely Elevated : > 320 mOsm/kg

Mental Status Alert to drowsy; Kussmaul respirations, fruity breath Stupor, profound lethargy, or coma; focal neurological signs

Typical Fluid Deficit 4 to 6 L (100 mL/kg) 8 to 12 L (150–200 mL/kg)

Note

Effective Serum Osmolality Equation : Osm eff = 2 × [ Na + ] + [ Glucose (mmol/L) ] \text{Osm}_{\text{eff}} = 2 \times [\text{Na}^+] + [\text{Glucose (mmol/L)}] Osm eff ​ = 2 × [ Na + ] + [ Glucose (mmol/L) ] Note that blood urea nitrogen (BUN) is omitted from effective osmolality calculations because urea is a freely permeable solute that diffuses across cell membranes without creating an effective transcellular osmotic gradient.

Critical Resuscitation Protocols: Fluids, Potassium Gates, and Insulin Transitions

The acute medical management of DKA and HHS requires a prioritized, multi-step resuscitation algorithm: DKA/HHS EMERGENCY RESUSCITATION GATES

  • 1. FLUID RESUSCITATION • Hour 1: 1000 - 1500 mL 0.9% Normal Saline (NS) IV
  • (IMMEDIATE FIRST STEP) • Then 250 - 500 mL/hr of 0.45% or 0.9% NS based on corrected sodium
  • │
  • ▼

2. POTASSIUM SAFETY GATE • CHECK SERUM POTASSIUM BEFORE STARTING INSULIN!

  • (CRITICAL GATE) • If K+ < 3.3 mmol/L: HOLD INSULIN! Infuse IV KCl 20-40 mEq/hr
  • If K+ 3.3 - 5.0 mmol/L: Start insulin + add 20-30 mEq KCl/L fluid
  • If K+ > 5.0 mmol/L: Start insulin; do not add potassium; check q1-2h
  • │
  • ▼
  • 3. IV REGULAR INSULIN • Regular insulin infusion: 0.1 units/kg/hr IV continuous
  • (AFTER POTASSIUM SAFE) • Target blood glucose decline rate: 3.0 to 5.0 mmol/L per hour
  • │
  • ▼

4. GLUCOSE PRESERVATION • When BG reaches ~14.0 mmol/L (DKA) or ~16.5 mmol/L (HHS):

(PREVENT BRAIN EDEMA) ADD 5% DEXTROSE (D5W) TO IV FLUIDS

  • Keep insulin running to close anion gap and clear ketonemia!
  • │
  • ▼
  • 5. SUBCUTANEOUS OVERLAP • DKA Resolved: BG < 14, pH > 7.30, HCO3 ≥ 18, Anion Gap normal
  • (PREVENT REBOUND) • INJECT SC BASAL INSULIN 2 TO 4 HOURS BEFORE STOPPING IV INFUSION
  • Step 1: Fluid Resuscitation (Priority One)

Intravenous fluid expansion must precede or accompany insulin administration to restore intravascular volume, improve tissue perfusion, and re-establish glomerular filtration. Administer 0.9% Normal Saline (NS) at 1000 to 1500 mL during the first hour. Subsequently, calculate corrected sodium:

Corrected [ Na + ] = Measured [ Na + ] + 0.3 × ( Glucose − 5.5 ) \text{Corrected } [\text{Na}^+] = \text{Measured } [\text{Na}^+] + 0.3 \times (\text{Glucose} - 5.5) Corrected [ Na + ] = Measured [ Na + ] + 0.3 × ( Glucose − 5.5 )

If corrected sodium is normal or elevated, switch maintenance fluids to 0.45% NS at 250 to 500 mL/hr. If corrected sodium is low, maintain 0.9% NS.

Step 2: The Absolute Potassium Safety Gate

Insulin drives potassium from the extracellular space into intracellular compartments via stimulation of the Na+/K+-ATPase pump. Additionally, rehydration dilutes extracellular potassium and enhances urinary potassium excretion.

If Serum K+ < 3.3 mmol/L : HOLD INSULIN COMPLETELY . Administer IV potassium chloride at 20 to 40 mEq/hr until serum potassium rises above 3.3 mmol/L. Administering insulin to a severely hypokalemic patient can trigger fatal cardiac arrhythmias (ventricular fibrillation, torsades de pointes) or acute respiratory arrest secondary to diaphragm paralysis.

If Serum K+ is 3.3 to 5.0 mmol/L : Initiate insulin infusion concurrently with IV fluid containing 20 to 30 mEq KCl per liter to maintain serum potassium safely between 4.0 and 5.0 mmol/L.

If Serum K+ > 5.0 mmol/L : Start insulin infusion without supplemental potassium; monitor serum potassium every 1 to 2 hours until levels decline below 5.0 mmol/L.

Step 3: Intravenous Regular Insulin Infusion

Administer continuous intravenous regular human insulin at a fixed rate of 0.1 units/kg/hr (or an initial IV bolus of 0.1 units/kg followed by 0.1 units/kg/hr). Target a steady glucose reduction rate of 3.0 to 5.0 mmol/L per hour .

If blood glucose fails to decline by at least 3.0 mmol/L in the first 2 to 4 hours despite adequate fluid resuscitation, double the hourly insulin infusion rate.

Step 4: Dextrose Addition and Prevention of Cerebral Edema

When blood glucose drops to ≈ 14.0 mmol/L in DKA (or ≈ 16.5 mmol/L in HHS), add 5% Dextrose to IV replacement fluids (e.g., 5% Dextrose with 0.45% NS) and adjust the insulin infusion rate downward to 0.05 units/kg/hr.

Caution

Never Stop the Insulin Infusion Early in DKA : Insulin is required not merely to lower glucose, but to suppress lipolysis and eliminate ketoacidosis. If blood glucose normalizes while the patient remains acidotic (bicarbonate < 18 mmol/L, open anion gap), continue the insulin infusion and increase the IV dextrose concentration (10% Dextrose). Stopping insulin prematurely causes rapid relapse of ketoacidosis.

Cerebral Edema Alert : Overly rapid reductions in plasma osmolality cause water to shift into relatively hyperosmolar brain parenchyma, precipitating cerebral edema (manifesting as headache, lethargy, bradycardia, hypertension, or sudden neurological collapse, primarily in children and young adults). Prevent by maintaining plasma glucose drop rates ≤ 5.0 mmol/L/hr and maintaining blood glucose at 11.0–14.0 mmol/L until ketoacidosis resolves. Emergency treatment: IV Mannitol (0.5 to 1.0 g/kg) or 3% hypertonic saline.

Step 5: Transition to Subcutaneous Insulin

Resolution of DKA is defined by:

  • Blood glucose < 14.0 mmol/L;
  • Venous pH > 7.30;
  • Serum bicarbonate ≥ 18 mmol/L; and

Normalization of the serum anion gap (≤ 12 mmol/L).

When DKA has resolved and the patient is alert and able to eat, transition to a subcutaneous regimen. The subcutaneous basal insulin must be injected 2 to 4 hours before discontinuing the intravenous insulin infusion . Because intravenous regular insulin has an elimination half-life of only 5 to 9 minutes, stopping the infusion without an active subcutaneous basal depot produces an immediate absolute insulin deficit, precipitating rebound hyperglycemia and recurrent ketoacidosis within hours.